The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Preclinical evaluation of selective inhibitors of nuclear export (SINE) in basal-like breast cancer (BLBC).
Dilara McCauley
Employment or Leadership Position - Karyopharm Therapeutics
Yosef Landesman
Employment or Leadership Position - Karyopharm Therapeutics
William Senapedis
Employment or Leadership Position - Karyopharm Therapeutics
Trinayan Kashyap
Employment or Leadership Position - Karyopharm Therapeutics
Jean-Richard Saint-Martin
Employment or Leadership Position - Karyopharm Therapeutics
Louis Plamondon
Employment or Leadership Position - Karyopharm Therapeutics
Vincent Sandanayaka
Employment or Leadership Position - Karyopharm Therapeutics
Sharon Shechter
Employment or Leadership Position - Karyopharm Therapeutics
Doriana Froim
Employment or Leadership Position - Karyopharm Therapeutics
Raphael Nir
Consultant or Advisory Role - Karyopharm Therapeutics (U)
Stock Ownership - Karyopharm Therapeutics
Jennifer Williams
No relevant relationships to disclose
Lynda Chin
Consultant or Advisory Role - Karyopharm Therapeutics
Stock Ownership - Karyopharm Therapeutics
Cyril Benes
No relevant relationships to disclose
Mansoor Raza Mirza
Employment or Leadership Position - Karyopharm Therapeutics
Stock Ownership - Karyopharm Therapeutics
Michael Kauffman
Employment or Leadership Position - Karyopharm Therapeutics
Stock Ownership - Karyopharm Therapeutics
Sharon Shacham
Employment or Leadership Position - Karyopharm Therapeutics
Stock Ownership - Karyopharm Therapeutics